“We believe our achievements from this past quarter, including capacity ... Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize ...

During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s performance for the quarter ... Legend is building an end-to-end cell therapy company by ...

CARVYKTI ® net trade sales of approximately $334 million and $963 million for the fourth quarter and full ... Centered in the US, Legend is building an end-to-end cell therapy company by ...

We use Adjusted Net Loss and Adjusted Net Loss per Share (which we sometimes refer to as “Adjusted EPS” “ANL per Share”) as performance metrics. Adjusted Net Loss and ANL per share are not ...